Author

Yu. N. Linkova

Observed names: Y. Linkova, Y.N. Lin’kova, Yu N Linkova, Yu. Linkova, Yu. N. Lin'kova, Yu. N. Lin’kova, Yu.N. Linkova, Yu.N. Lin’kova, Yulia Linkova, Yulia N. Lin'kova, Yulia N. Linkova, Yulia N. Lin’kova, Линькова Ю. Н., Ю. Н. Линькова

Institution: BIOCAD (Russia)

Observed institutions: Saint-Petersburg State University of Telecommunications, BIOCAD (India), BIOCAD (Russia)

ORCID: 0000-0002-5463-1022

Observed ORCIDs: 0000-0002-5463-1022, 0000-0003-3628-4626

OpenAlex ID: A5110495384

The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study

2021 · Nikita V. Lomakin, Bulat A. Bakirov, et al. · Inflammation Research · 58

PDF

Results of a phase 1 clinical study of anti-CD20 monoclonal antibody (BCD-132): pharmacokinetics, pharmacodynamics and safety

2019 · O.V. Boyko, A.N. Boyko, et al. · S S Korsakov Journal of Neurology and Psychiatry · 22

Effectiveness and safety of BCD180, anti-TRBV9+ T-lymphocytes monoclonal antibody in patients with active radiographic axial spondyloarthritis: 36-week results of double-blind randomized placebo-controlled phase II clinical study ELEFTA

2024 · E. L. Nasonov, V. I. Mazurov, et al. · Rheumatology Science and Practice · 18

PDF

Efficacy and safety of levilimab in combination with methotrexate in subjects with rheumatoid arthritis: Results of phase II AURORA study

2021 · V. I. Mazurov, E. G. Zotkin, et al. · Rheumatology Science and Practice · 18

PDF

The Efficacy and Safety of BCD-180, an Anti-TRBV9+ T cell Monoclonal Antibody, in Patients with Active Radiographic Axial Spondyloarthritis: 36-week Results from the Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study ELEFTA

2025 · E. L. Nasonov, V. I. Mazurov, et al. · Doklady Biochemistry and Biophysics · 16

Efficacy and safety of antiCD20 monoclonal antibody divozilimab during 48-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS

2023 · A.N. Boyko, V.M. Alifirova, et al. · S S Korsakov Journal of Neurology and Psychiatry · 14

Effectiveness and safety of levilimab in combination with methotrexate in treatment of patients with active rheumatoid arthritis resistant to methotrexate monotherapy (double-blinded randomized placebo controlled phase III clinical study SOLAR)

2021 · V. I. Mazurov, M. A. Korolev, et al. · Modern Rheumatology Journal · 14

PDF

Long-term efficacy and safety of divozilimab during 2-year treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-4/MIRANTIBUS

2024 · A.N. Boyko, V.M. Alifirova, et al. · S S Korsakov Journal of Neurology and Psychiatry · 13

PDF

Efficacy and safety of divozilimab during 24-week treatment of multiple sclerosis patients in randomized double-blind placebo-controlled clinical trial BCD-132-2

2023 · A.N. Boyko, V.M. Alifirova, et al. · S S Korsakov Journal of Neurology and Psychiatry · 13

Prolgolimab with chemotherapy as first-line treatment for advanced non-squamous non-small-cell lung cancer

2025 · K. Laktionov, A. Smolin, et al. · European Journal of Cancer · 12

Efficacy and safety of sampeginterferon β-1a in the treatment of relapsing remitting multiple sclerosis: results of 52 weeks of therapy in a randomized, double-blind clinical trial

2022 · A.N. Boyko, O.V. Boyko, et al. · S S Korsakov Journal of Neurology and Psychiatry · 10

The new pegylated interferon beta-1a (sampeginterferon beta-1a, BCD-054) in the treatment of remitting multiple sclerosis

2019 · A. N. Boyko, K. Z. Bakhtiyarova, et al. · S S Korsakov Journal of Neurology and Psychiatry · 10

Netakimab for the treatment of psoriatic arthritis: 3-year results of the phase III BCD-085-8/PATERA study

2024 · T. V. Korotaeva, V. I. Mazurov, et al. · Modern Rheumatology Journal · 7

PDF

Efficacy and safety of nurulimab+prolgolimab with continued prolgolimab therapy compared to prolgolimab alone as first-line therapy in patients with unresectable or metastatic melanoma: final results of the phase II OBERTON clinical study

2023 · Igor V. Samoylenko, Lev V. Demidov, et al. · Journal of Modern Oncology · 7

PDF

A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT)

2024 · Lev Demidov, Galina Kharkevich, et al. · Frontiers in Oncology · 6

PDF

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)

2023 · M. Yu. Fedyanin, A. V. Snegovoy, et al. · Safety and Risk of Pharmacotherapy · 6

PDF

Improved clinical outcomes with low-dose anti-CTLA-4 (Nurulimab) plus anti-PD-1 (Prolgolimab) vs. anti-PD-1 monotherapy in advanced cutaneous melanoma: Results from the phase III OCTAVA trial

2025 · Lev Demidov, Igor Samoylenko, et al. · European Journal of Cancer · 5

Efficacy and Safety of Levilimab in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: 56-Week Results of Phase III Randomized Double-Blind Placebo-Controlled Trial SOLAR

2024 · V. I. Mazurov, E. L. Nasonov, et al. · Doklady Biochemistry and Biophysics · 5

Efficacy and safety of levilimab in combination with methotrexate in patients with active rheumatoid arthritis: 56-week results of phase III randomized double-blind placebo-controlled trial SOLAR

2023 · V. I. Mazurov, A. M. Lila, et al. · Rheumatology Science and Practice · 5

PDF

Efficacy, tolerability and safety of the treatment with teberif: the results of a 2-year randomized clinical trial of treatment naïve patients with remitting multiple sclerosis, who have not received DMT, after switching from other interferon β-1a

2019 · A. N. Boyko, L. P. Bosenko, et al. · S S Korsakov Journal of Neurology and Psychiatry · 5

Results of 4 years of therapy with divozilimab in patients with relapsing multiple sclerosis

2025 · A.N. Boyko, V.M. Alifirova, et al. · S S Korsakov Journal of Neurology and Psychiatry · 4

Abstract 653: Proved clinical benefit of low-dose anti-CTLA4 + anti-PD-1 immunotherapy versus mono anti-PD-1 therapy in patients unresectable or metastatic melanoma: Phase III OCTAVA trial

2025 · Lev Demidov, Igor Samoylenko, et al. · Cancer Research · 4

Long-term Efficacy and Safety of Sampeginterferon-β1a in the Treatment of Relapsing Remitting Multiple Sclerosis: a Randomized, Double-Blind Clinical Trial 104-Week Results

2023 · A.N. Boyko, K.Z. Bakhtiyarova, et al. · S S Korsakov Journal of Neurology and Psychiatry · 4

Retrospective analysis of the natural history of type 1 spinal muscular atrophy in children

2021 · D. V. Vlodavets, N. V. Ganina, et al. · Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics) · 4

PDF

A comparative placebo-controlled clinical study on the efficacy and safety of interferon beta-1a for subcutaneous injections in patients with remitting multiple sclerosis: results of the first year of observations

2017 · A. N. Boyko, L. P. Bosenko, et al. · S S Korsakov Journal of Neurology and Psychiatry · 4

Works count: 60

Citation count: 310

H-index: 10

I10-index: 12